Prognostic Role of Interferon‐λ3 in Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis‐Associated Interstitial Lung Disease
Authors' conclusion
Serum IFNλ3 is a promising biomarker for identifying patients at high risk of poor outcomes in anti-MDA5 antibody-positive DM-ILD.
Study context
- Population
- Patients with PM/DM-associated interstitial lung disease (ILD) (derivation and validation cohorts) and controls; mortality analysis in anti-MDA5 antibody-positive DM-ILD79 anti-MDA5+ DM-ILD
- Participants
- 221 patients
- Comparison
- High vs low serum IFNλ3 levels in anti-MDA5 antibody-positive DM-ILD
- Outcome
- Mortality risk (survival) in anti-MDA5 antibody-positive DM-ILD
Methodological detailsderivation and validation cohorts, multivariate analysis, lung pathologic analyses
- Derivation and validation cohorts
- Multivariate analysis
- Lung pathologic analyses
Performance
As reported in the abstract
Survival in anti-MDA5 antibody-positive DM-ILD
- High IFNλ3 (>120 pg/mL) had significantly lower survival rates than low IFNλ3 (≤120 pg/mL)
- Multivariate analysis: high IFNλ3, old age and low Pao2 significantly associated with poor prognosis
- Old age (>53 years), high IFNλ3 (>120 pg/mL) and low Pao2 (<75 mm Hg) had the worst survival
Further findings
Serum IFNλ3 at diagnosis, PM/DM-ILD vs healthy controls
- Significantly higher in PM/DM-ILD than in healthy controls
- Specifically increased in anti-MDA5 antibody-positive DM-ILD in both derivation and validation cohorts
Lung pathology, IFNλ3 staining
- IFNλ3-positive staining in macrophages, airway epithelial cells, pleural region and intrapulmonary veins in anti-MDA5+ DM-ILD
Original publication
Prognostic Role of Interferon‐λ3 in Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis‐Associated Interstitial Lung Disease. Arthritis Rheumatol. Published 6 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →